ÄÐÐÔµÄǿʢ£¬£¬ £¬£¬£¬ÔÚÓÚ´ÓÈÝ¡ª¡ª¡ªÏ²±¨£¡º£ÄÚÊ׸ö£¡Î÷°àÑÀÔ­ÑÐÈë¿ÚèÛéÚËáÎ÷µØÄǷǿڷþ»ìÐüÒº»ñÅúÉÏÊУ¡-½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬ £¬£¬£¬ÂȵªÆ½"> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬ £¬£¬£¬ÂȵªÆ½ ÒøÐÓÒ¶,Þ½ÏãÕýÆøË®,ŵ·úɳÐÇ,ÂȵªÆ½,ÑÎËáÂȱûàº,С¶ùÖ¹¿ÈÌǽ¬,Í·æß¿ËÂå¿ÅÁ£,ºìÂÝÃ¹ËØ¿ÅÁ£,Å£»£»£»£»£»£»ÇËá¿ÅÁ£,Í´¾­Äþ¿ÅÁ£,ÐÂÉú»¯¿ÅÁ£,°¢¹éÑøÑªÌǽ¬,½ðÒø»¨Â¶"> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬ £¬£¬£¬ÂȵªÆ½"> ÄÐÐÔµÄǿʢ£¬£¬ £¬£¬£¬ÔÚÓÚ´ÓÈÝ¡ª¡ª¡ªÏ²±¨£¡º£ÄÚÊ׸ö£¡Î÷°àÑÀÔ­ÑÐÈë¿ÚèÛéÚËáÎ÷µØÄǷǿڷþ»ìÐüÒº»ñÅúÉÏÊУ¡-½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬ £¬£¬£¬ÂȵªÆ½"> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬ £¬£¬£¬ÂȵªÆ½ ÒøÐÓÒ¶,Þ½ÏãÕýÆøË®,ŵ·úɳÐÇ,ÂȵªÆ½,ÑÎËáÂȱûàº,С¶ùÖ¹¿ÈÌǽ¬,Í·æß¿ËÂå¿ÅÁ£,ºìÂÝÃ¹ËØ¿ÅÁ£,Å£»£»£»£»£»£»ÇËá¿ÅÁ£,Í´¾­Äþ¿ÅÁ£,ÐÂÉú»¯¿ÅÁ£,°¢¹éÑøÑªÌǽ¬,½ðÒø»¨Â¶">

½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú

ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

ÄÐÐÔµÄǿʢ£¬£¬ £¬£¬£¬ÔÚÓÚ´ÓÈÝ¡ª¡ª¡ªÏ²±¨£¡º£ÄÚÊ׸ö£¡Î÷°àÑÀÔ­ÑÐÈë¿ÚèÛéÚËáÎ÷µØÄǷǿڷþ»ìÐüÒº»ñÅúÉÏÊУ¡

ÈÕÆÚ£º

2026Äê04ÔÂ03ÈÕ 14:35


èÛéÚËáÎ÷µØÄǷǿڷþ»ìÐüÒº£¨ÐÒ·ö½¡®£©ÉÏÊÐÉêÇëÕýʽ»ñÅú¡£¡£¡£¡£¡£×÷Ϊº£ÄÚÊ׸ö¿Ú·þ»ìÐüÒº¼ÁÐ͵ÄÎ÷µØÄÇ·Ç£¬£¬ £¬£¬£¬Õâ¿îÓÉÎ÷°àÑÀÔ­ÑÐÉú²úµÄ²úÆ·£¬£¬ £¬£¬£¬²»µ«Ìî²¹ÁËED£¨²ªÆð¹¦Ð§Õϰ­£©ÖÎÁÆÁìÓòµÄ¼ÁÐÍ¿Õȱ£¬£¬ £¬£¬£¬¸ü±ê¼Ç×ÅÄÐÐÔ¿µ½¡¹ÜÀíÂõÈëÁ˾«×¼¿ØÁ¿¡¢ÌåÑéÓÅÏȵÄн׶Ρ£¡£¡£¡£¡£Ëü¼È·ÇÈ«ÐÂÒòËØ£¬£¬ £¬£¬£¬Ò²·ÇÊ׷£¬£¬ £¬£¬£¬¶øÊÇÖ±»÷»¼Õßδ±»Öª×ãµÄÓÃÒ©ÐèÇ󣬣¬ £¬£¬£¬ÒÔ¸ÄÁ¼ÐÍÐÂÒ©µÄ×Ë̬£¬£¬ £¬£¬£¬ÖØÐ½ç˵·þÒ©ÌåÑé——¸üÓÐÓ㬣¬ £¬£¬£¬¸üÌåÃæ£¬£¬ £¬£¬£¬¸ü´ÓÈÝ¡£¡£¡£¡£¡£

 

Ò»¡¢Êг¡ÏÖ×´£ºEDÖÎÁÆÐèÇóÏÔÖø£¬£¬ £¬£¬£¬¹Å°åÓÃÒ©Í´µãÈÔ´æ

 

ÏÖ½×¶Î,EDÒѳÉΪӰÏìÄÐÐÔÉúÑÄÖÊÁ¿µÄÖ÷ÒªÎÊÌâÖ®Ò»¡£¡£¡£¡£¡£ÔÚÎÒ¹úÓÐ×ÅÖØ´óµÄ»¼Õß»ùÊý¡£¡£¡£¡£¡£¾Ý¹ûÕæÊý¾ÝÏÔʾ£¬£¬ £¬£¬£¬ÎÒ¹úED»¼ÕßÈËÊýÔ¼1.4ÒÚÈË¡£¡£¡£¡£¡£¾Ý¡¶2024ÄêÖйú¿¹EDÒ©ÎïÐÐÒµ°×ƤÊé¡·ÏÔʾ£¬£¬ £¬£¬£¬31-40ËêÄÐÐÔÕ¼±È44.79%£¬£¬ £¬£¬£¬21-30ËêȺÌåÒ²µÖ´ï38.03%£¬£¬ £¬£¬£¬·ºÆðÄêÇữÇ÷ÊÆ¡£¡£¡£¡£¡£

´ÓÊг¡¹æÄ£À´¿´£¬£¬ £¬£¬£¬EDÒ©ÎïÈüµÀÌåÁ¿¿É¹Û£¬£¬ £¬£¬£¬¶øÎ÷µØÄÇ·ÇÔÚËùÓÐEDÀàÒ©ÎïÊг¡Õ¼±È¶ÀÙÆ°ÁÍ·£¬£¬ £¬£¬£¬2024ÄêÕ¼±È¸ß´ï71.96%¡£¡£¡£¡£¡£×÷ΪPDE5ÒÖÖÆ¼ÁµÄ½¹µãÆ·À࣬£¬ £¬£¬£¬Î÷µØÄǷǸüÊDZ»º£ÄÚÍâ¶àÏîȨÍþÖ¸ÄÏ£¨Èç¡¶²ªÆð¹¦Ð§Õϰ­Õï¶ÏÓëÖÎÁÆÖ¸ÄÏ¡·¡¶Å·ÖÞÃÚÄòѧ»áÐÔÓëÉúÖ³¿µ½¡Ö¸ÄÏ¡·µÈ£©ÁÐΪEDÖÎÁƵÄÊ×ѡҩÎ£¬ £¬£¬£¬ÆäÓÐÓÃÐÔÓëÇå¾²ÐÔÒÑ»ñµÃÆÕ±éÑéÖ¤¡£¡£¡£¡£¡£

Ö»¹Ü¿Ú·þPDE5ÒÖÖÆ¼ÁÊÇEDÖÎÁƵÄÖ÷Á÷Ñ¡Ôñ£¬£¬ £¬£¬£¬ÇÒ38.64%µÄÄÐÐÔÔø·þÓùý¿¹EDÒ©Îï1£¬£¬ £¬£¬£¬µ«¹Å°åƬ¼ÁµÄÍ´µãʼÖÕÄÑÒÔ½â¾ö£¬£¬ £¬£¬£¬³ÉΪ»¼ÕßÓÃÒ©µÄÒþÐÎÃż÷£º

¼ÁÁ¿Àο¿£ºÏÖÓе¥ºÐ°ü×°¼ÁÐͼÁÁ¿¾ùÒÑÀο¿£¬£¬ £¬£¬£¬ÎÞ·¨Æ¥Åä¸öÌ廯ÐèÇ󣻣»£»£»£»£»

ÐèË®ËÍ·þ£ºÎÞ·¨Öª×ãÎÞË®Ìõ¼þÏÂËæÊ±ËæµØÔ½·¢±ã½Ý¸øÒ©£»£»£»£»£»£»

Òþ˽ÞÏÞΣºÒ©Æ¬°ü×°Ò×̻¶Òþ˽£¬£¬ £¬£¬£¬ÓÈÆäÔÚÉç½»³¡¾°ÏÂÓÃÒ©±ãµ±ÐÔ´ó·ùϽµ£»£»£»£»£»£»

ÍÌÑÊÕϰ­£ºÔ¼40.2£¥µÄÄÐÐÔ±£´æÍÌÑÊÄÑÌâ2£¬£¬ £¬£¬£¬Æ¬¼ÁÄÑÒÔÖª×ãÍÌÑÊÕϰ­ÕßÓÃÒ©ÐèÇ󡣡£¡£¡£¡£

 

¶þ¡¢ÐÒ·ö½¡®£ºÒÔ¸ÄÁ¼ÊµÏÖÌåÑéÉý¼¶¾«×¼»÷ÖÐÁÙ´²Í´µã

 

ÐÒ·ö½¡®µÄÉÏÊУ¬£¬ £¬£¬£¬ÕýÊǶÔÕâËÄ´óÍ´µãµÄ¾«×¼»ØÓ¦£º 

¾«×¼¼ÁÁ¿¶¨ÖÆ£º¼ÁÁ¿¿Éƾ֤ÐèÇóÎÞаµ÷Àí£¬£¬ £¬£¬£¬25-100mg×ÔÓɵ÷½â£¬£¬ £¬£¬£¬Æ¥Åä¸öÐÔ»¯ÐèÇ󣻣»£»£»£»£»

ʹÓÃÀû±ã¿ì½Ý£ºÎ¢·Û»¯Êèɢϵͳ£¬£¬ £¬£¬£¬ÎÞÐèË®ËÍ·þ£¬£¬ £¬£¬£¬ËæÊ±ËæµØÍê³É¸øÒ©£¬£¬ £¬£¬£¬ÊÊÅä¶àÔªÉúÑij¡¾°£»£»£»£»£»£»

È«ÐÂÓÃÒ©ÌåÑ飺°Ñ“͵͵ÃþÃþÍÌÆ¬”Éý¼¶Îª“×ÆË¸Õý´ó¿ÚÅç¸øÒ©”£¬£¬ £¬£¬£¬½â¾öÉç½»³¡¾°µÄÒþ˽ÞÏÞΡ£¡£¡£¡£¡£

ÊÊÓÃÈËȺÆÕ±é£ºÌØÊâÊʺÏÍÌÑÊÄÑÌâ¡¢Ðè׼ȷ¼ÁÁ¿µ÷½âµÄʹÓÃÕß

 

Èý¡¢´Ó“ÓÐÓÔµ½“ºÃÓÔ£ºÒ»³¡¹ØÓÚ·þÒ©ÌåÑéµÄÀíÄî¸ïÃü

 

ÐÒ·ö½¡®µÄ»ñÅú£¬£¬ £¬£¬£¬Ô¶·ÇÒ»´Î¼òÆÓµÄ¼ÁÐ͸ÄÁ¼£¬£¬ £¬£¬£¬¶øÊÇÒ»³¡¹ØÓÚEDÖÎÁƵÄÀíÄî¸ïÃü——ÎÒÃÇÕýÔÚÖØÐ½ç˵ʲô²ÅÊÇ“ºÃÒ©”¡£¡£¡£¡£¡£

ºã¾ÃÒÔÀ´£¬£¬ £¬£¬£¬Ò½Ò©ÐÐÒµÖ´×ÅÓÚ×·ÇóÒ©ÎïµÄ“ÓÐÓÃÐÔ”£¬£¬ £¬£¬£¬È´ÍùÍùºöÂÔÁË“¿ÉÓÃÐÔ”¡£¡£¡£¡£¡£µ±»¼ÕßÐèÒªêþҩƬ¡¢ÕÒË®±­¡¢ÅÌËãʱ¼ä¡¢ÌÓ±ÜÑÛ¹âʱ£¬£¬ £¬£¬£¬Ò©ÎïµÄÁÆÐ§ÒÑÔÚ²ã²ãÕÛËðÖдòÁËÕÛ¿Û¡£¡£¡£¡£¡£

ÐÒ·ö½¡®µÄ·ºÆð£¬£¬ £¬£¬£¬±ê¼Ç×ÅEDÖÎÁÆÕýʽ´Ó“·þÒ©Öβ¡”µÄ1.0ʱ´ú£¬£¬ £¬£¬£¬ÂõÈë“ÌåÑéÓÅÏÈ”µÄ2.0ʱ´ú¡£¡£¡£¡£¡£Õâ²»µ«ÊÇÊÖÒÕµÄǰ½ø£¬£¬ £¬£¬£¬¸üÊǼÛÖµ¹ÛµÄת±ä£º

  • ´Ó“»¼Õß˳ӦҩÎ½“Ò©Îï˳Ӧ»¼Õß”

  • ´Ó“¼òµ¥¼ÁÁ¿”µ½“¸öÐÔ»¯¼Æ»®”

  • ´Ó“Ò½ÁƳ¡¾°”µ½“ÉúÑij¡¾°”

  • ´Ó“Öβ¡”µ½“ÖÎÐÄ”

“¸úÓÐÇéÈË×ö¿ìÀÖÊ£¬£¬ £¬£¬£¬±ðÎÊÊǽÙÊÇÔµ¡£¡£¡£¡£¡£”Õâ¾äÀ´×Ô¡¶Á÷¹â°¿Ïè¡·µÄ¸è´Ê£¬£¬ £¬£¬£¬µÀ¾¡ÁËÈËÊÀÇé°®µÄ´¿´âÓëäìÈ÷¡£¡£¡£¡£¡£¶øÒ»·Ý´ÓÈÝµÄµ×Æø£¬£¬ £¬£¬£¬ÕýÊÇÕâ“¿ìÀÖÊ”×îºÃµÄ×îÏÈ¡£¡£¡£¡£¡£

ÏÖÔÚ£¬£¬ £¬£¬£¬ÐÒ·ö½¡® ÔÚÒ½Ò©ÁìÓòÕÒµ½ÁËеÄ×¢½Å——ÕæÕýµÄÖÎÁÆ£¬£¬ £¬£¬£¬Ó¦µ±Èû¼ÕßÔÚ×·Çó¿µ½¡µÄõè¾¶ÉÏ£¬£¬ £¬£¬£¬±£ÓÐÓ¦ÓеĴÓÈÝÓëÌåÃæ¡£¡£¡£¡£¡£

ÎÒÃÇÆÚ´ýÓë¸÷½çЯÊÖ£¬£¬ £¬£¬£¬ÈÃÕⳡʼÓÚ¼ÁÐ͵ÄÀå¸ï£¬£¬ £¬£¬£¬×îÖÕÒý·¢Õû¸öÐÐÒµ¶Ô»¼ÕßÌåÑéµÄÖØÐ¹Ø×¢¡£¡£¡£¡£¡£ÓÉÓÚ£¬£¬ £¬£¬£¬×îºÃµÄÒ©£¬£¬ £¬£¬£¬²»µ«ÊÇÄÜÈò¡ÈËȬÓúµÄÒ©£¬£¬ £¬£¬£¬¸üÊÇÈò¡ÈËÔ¸Òâ¼á³Ö·þÓõÄÒ©¡£¡£¡£¡£¡£

×ÊÁÏȪԴ

1¡¢2024ÄêÖйú¿¹EDÒ©ÎïÐÐÒµ°×ƤÊé

2¡¢Pharmacokinetic Parameters of a Novel SildenafiOral Liquid Suspension Administered to HealthyAdult Men Under Fasted Conditions

3¡¢ÖйúÌØ¶¨ÈËȺÍÌÑʹ¦Ð§Õϰ­µÄÊ¢Ðв¡Ñ§ÊӲ챨¸æ.ÖлªÎïÀíҽѧÓ뿵ÅÓºêÔ¸2017Äê12ÔµÚ39¾íµÚ12ÆÚ

4¡¢Ã×ÄÚÍøÊý¾Ý¿â¡¢²úÆ·ÁÙ´²Ñо¿Êý¾Ý

Ïà¹ØÍÆ¼ö

ÍøÕ¾µØÍ¼